Episode 66: Fenebrutinib in PPMS: Insights from ACTRIMS Forum 2026

Clinical trial results unveiled today at ACTRIMS Forum 2026 suggest that BTK inhibition may help bridge relapsing and progressive MS biology, targeting both peripheral immune activity and compartmentalised CNS processes driving disease progression.

In this exclusive episode providing the first expert discussion of the complete dataset, Fenebrutinib PPMS trial leads Prof. Amit Bar-Or (University of Pennsylvania) and Dr. Stephen Hauser (University of California San Francisco) break down what the fenebrutinib results really show. Together, they explore:

• Why BTK inhibition is uniquely positioned to address progressive MS biology
• How fenebrutinib compared to ocrelizumab in a Phase 3 PPMS trial
• What the data suggest for patients with non-relapsing, chronic disease

Listen for a deep dive into the science and the clinical implications.